Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Lab-on-a-Chip and Microfluidics: Emerging Themes, Technologies and Applications
Conferences  \  Lab-on-a-Chip & Microfluidics World Congress 2017  \  Lab-on-a-Chip and Microfluidics: Emerging Themes, Technologies and Applications  \  Agenda  \  Ibrahim Ozbolat
RegisterLogin

Ibrahim Ozbolat's Biography


Ibrahim Ozbolat, Hartz Family Associate Professor of Engineering Science and Mechanics, The Huck Institutes of the Life Sciences, Penn State University

Ibrahim Tarik Ozbolat is a Hartz Family Associate Professor of Engineering Science and Mechanics, Biomedical Engineering and Neurosurgery, and a member of the Huck Institutes of the Life Sciences at Penn State University. Dr. Ozbolat’s main area of research is in the field of 3D Bioprinting. He has been working on several aspects of bioprinting such as bioprinting processes, bioink materials, bioprinters and post-bioprinting tissue maturation for manufacturing of more than a dozen tissues and organs. Dr. Ozbolat is a leading scientist with over 120 publications, including a sole-authored book in his domain. Due to his notable contributions to the field of bioprinting, he has received several prestigious international and national awards including 2014 NSF CAREER Award, 2014 SME Outstanding Young Manufacturing Engineer Award, 2014 ASME Chao and Trigger Young Manufacturing Engineer Award, 2014 ASME Tau Pi Sigma Gold Medal, 2015 IIE Dr. Hamid K. Eldin Outstanding Early Career Industrial Engineer in Academia Award, 2015 International Outstanding Young Researcher in Freeform and Additive Manufacturing Award and 2017 Hartz Family Career Development Professorship at Penn State.

Ibrahim Ozbolat Image

Bioprinting Pancreas-on-a-Chip

Tuesday, 3 October 2017 at 16:45

Add to Calendar ▼2017-10-03 16:45:002017-10-03 17:45:00Europe/LondonBioprinting Pancreas-on-a-ChipSELECTBIOenquiries@selectbiosciences.com

Despite the recent achievements in cell-based therapies for curing type-1 diabetes (T1D), vascularization of beta (ß)-cell clusters is still a major roadblock as it is essential for long-term viability and function of ß-cells in vivo. In this research, we report micro-vascularization within engineered pancreatic islets (EPIs) made of rodent cells. EPIs cultured in fibrin constructs maintained their viability and functionality over time while non-vascularized EPIs could not retain their viability nor functionality. We then bioprinted the EPIs along with bioprinted macro-vascular network in a pancreas-on-a-chip model. Here we demonstrate a proof-of-concept study for a vascularized pancreas-on-a-chip model for the first time, where patient specific stem cell-derived human beta cells can be vascularized in the near future for an effective treatment of T1D.

Add to Calendar ▼2017-10-02 00:00:002017-10-04 00:00:00Europe/LondonLab-on-a-Chip and Microfluidics: Emerging Themes, Technologies and ApplicationsSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors